QurAlis
Edit info- Founded: 2016
- Location: Cambridge, MA
- Employee range: 11 - 50
- Clinical stage: Clin1
- Therapy area: ALS
- Drug types: NEU
- Lead product: QRL-201
- Funding: $88M B Mar 2023; $42M May 2020; $5.5M Seed Nov 2018
- Investors: EQT Life Sciences, Droia Ventures, Sanofi Ventures, BioInnovation Capital, Viva Biotech Limited, Alexandria, Amgen, MP Healthcare Venture Management, ALS Investment Fund, LS Polaris Innovation Fund, Mission BioCapital, INKEF Capital, Dementia Discovery Fund, Amgen Ventures, MP Healthcare Venture Management, Mitsui Global Investment, Dolby Family Ventures, Mission Bay Capital, Sanford Biosciences
quralis.com linkedin.com job board
Business:
ALS cure - Small Molecules, ASO
Drug notes:
QRL-201/QRL-203 Clin0 FTD, Clin0 PLS; QRL-101 Clin1 ALS, Clin0 FTD; QRL-204 Clin0 ALS/FTD, Clin0 FTD
About:
QurAlis is using advances in precision medicine to develop therapeutics for neurodegenerative diseases. Amyotrophic lateral sclerosis (ALS), is a progressive neurodegenerative disease that reduces muscle function and control. By examining the disease-causing genetic alterations linked with ALS, QurAlis is targeting these disease mechanisms using human neuronal stem cell models from ALS patients - this includes the gene that encodes the protein TDP-43. QuAlis has a second platform, FlexASO, a proprietary anti-sense oligonucleotide splice modulator platform to selectively modulate RNA levels to change the expression of genes connected to disease. With these approaches, QurAlis has already established a pipeline of programs in clinical stages.
Jobs:
News:
2 months after launch, QurAlis nabs early ALS compounds ...
fiercebiotech.com
Dec 23, 2024
Science/business updates
external-link
QurAlis to Present at the Piper Sandler 35th Annual ...
crunchbase
Nov 26, 2023
Science/business updates
external-link
Splice switcher antisense oligonucleotides with modified backbone chemistries
crunchbase
Dec 2, 2022
Science/business updates
external-link
Phase 1 trial now testing 2 new QRL-201 doses in ALS patients - ALS News Today
googlenews
Dec 2, 2024
Science/business updates
external-link
QurAlis Doses First Patient With ALS in Phase 1 Clinical Trial Evaluating QRL-101, a First-in-Class Kv7 Precision Therapy for ALS - Yahoo Finance
googlenews
Dec 4, 2024
Science/business updates
external-link
Amgen backs Harvard professors' ALS startup QurAlis
fiercebiotech.com
Dec 23, 2024
Funding-related
external-link
Canadian initiative to advance AI tech to better diagnose ALS |...
crunchbase
Sep 26, 2023
Science/business updates
external-link
QurAlis secures $88M to advance ALS therapies - ALS News Today
googlenews
Mar 16, 2023
Funding-related
external-link
QurAlis Boosts World-Class Leadership Team With Addition of Three New Members - Business Wire
googlenews
May 26, 2021
New hires
external-link
QurAlis Grants Lilly Exclusive Global License for QRL-204, a Potentially First-in-Class Precision Therapy That Restores UNC13A Function in ALS and FTD - PR Newswire
googlenews
Jun 3, 2024
Funding-related
external-link
Lilly gilds neuro pipeline, paying QurAlis $45M for preclinical ALS, dementia prospect - Fierce Biotech
googlenews
Jun 3, 2024
Funding-related
external-link
QurAlis Strengthens Global Presence With Opening of European Headquarters That Includes R&D Manufacturing - PR Newswire
googlenews
Jan 3, 2024
Science/business updates
external-link
First group of healthy volunteers dosed in QRL-101 MAD study - ALS News Today
googlenews
Sep 16, 2024
Science/business updates
external-link
UMass Chan, QurAlis Corporation partnership expands on biomedical research by Joel Richter - UMass Medical School
googlenews
Jun 25, 2024
Science/business updates
external-link
Avidity drug for muscular dystrophy shows promise; Syntis takes new approach to weight loss - BioPharma Dive
googlenews
Jun 12, 2024
Science/business updates
external-link
#ALS/#MND Symposium 2024 is a wrap! QurAlis' CEO and founder Kasper Roet (center right side of the monitor) and several team members attended the 35th International Symposium on ALS/MND held last week
linkedin
Dec 16, 2024
Science/business updates
external-link
QurAlis to Present Data That Show its Splice-Switching ASOs Restore UNC13A Function in ALS and Frontotemporal Dementia - PR Newswire
googlenews
Mar 4, 2024
Science/business updates
external-link
QurAlis' ANQUR Clinical Trial of QRL-201 in ALS Advances to Dose Range-Finding (DRF) Phase With First Participant Dosed
crunchbase
Nov 19, 2024
Science/business updates
external-link
Phase 1 clinical trial of QRL-201 for ALS approved in the UK - ALS News Today
googlenews
Jul 18, 2023
Science/business updates
external-link
ALS-focused QurAlis raises $5.5M in seed money, wins ...
fiercebiotech.com
Dec 23, 2024
Funding-related
external-link
QurAlis Announces Expansion of its Selective Kv7.2/7.3 Ion Channel Opener, QRL-101, Into Epilepsy - PR Newswire
googlenews
Sep 19, 2024
Science/business updates
external-link
QurAlis Receives Clinical Trial Authorisation (CTA) in the U.K. ...
crunchbase
Jul 11, 2023
Science/business updates
external-link
QurAlis Announces First Patient Dosed With QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS - PR Newswire
googlenews
Apr 6, 2023
Science/business updates
external-link
QurAlis Announces First-in-Human Dose in Phase 1 Clinical Trial of QRL-101, a First-in-Class Kv7 Precision Therapy for ALS - PR Newswire
googlenews
Jan 5, 2023
Science/business updates
external-link
QurAlis to Participate in Upcoming Investor and Industry Conferences in September
crunchbase
Aug 21, 2024
Funding-related
external-link
Quralis provides update on QRL-201 for ALS
crunchbase
Dec 9, 2022
Science/business updates
external-link
QurAlis Corporation - Massachusetts Biotechnology Council
googlenews
Oct 23, 2020
New hires
external-link
QurAlis raises $42 Million Series A Financing to Develop New Therapies for Amyotrophic Lateral Sclerosis (ALS) - Business Wire
googlenews
May 13, 2020
Funding-related
external-link
QurAlis Licenses Eli Lilly’s Preclinical Compounds That Target Neuronal Excitotoxicity - ALS News Today
googlenews
Jul 9, 2020
Science/business updates
external-link
Treatment of neurological diseases using modulators of unc13a gene transcripts
crunchbase
Dec 2, 2022
Science/business updates
external-link
QurAlis Receives Health Canada Clinical Trial Application Authorization for QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS - PR Newswire
googlenews
Dec 8, 2022
Science/business updates
external-link
AES 2024 is a wrap! QurAlis' CBO Vikas Sharma, PhD (left) and sr. program manager Taylor Gray (right) attended the American Epilepsy Society (AES) Annual Meeting held last weekend. It was great to att
linkedin
Dec 23, 2024
Science/business updates
external-link
QurAlis Reveals Newest Program Targeting UNC13A RNA Mis-splicing Incorporating its FlexASO™ Platform - PR Newswire
googlenews
Mar 20, 2023
Science/business updates
external-link
QurAlis homes in on drug candidates for subset of ALS patients - Drug Discovery & Development
googlenews
Jan 11, 2023
Science/business updates
external-link
Eli Lilly licenses preclinical antisense program designed to treat ALS, dementia - Endpoints News
googlenews
Jun 3, 2024
Science/business updates
external-link
QurAlis nabs $42M funding round for ALS, frontotemporal ...
fiercebiotech.com
Dec 23, 2024
Funding-related
external-link
QurAlis links with Unlearn to leverage machine learning in ALS trials - Fierce Biotech
googlenews
Jun 28, 2023
Science/business updates
external-link
QurAlis to Present at the Stifel 2024 CNS Days
crunchbase
Mar 16, 2024
Science/business updates
external-link
QurAlis Closes $88 Million Series B Financing to Advance Precision Medicines for Neurodegenerative Diseases - PR Newswire
googlenews
Mar 9, 2023
Funding-related
external-link
QurAlis and Unlearn Announce Collaboration to Accelerate and Optimize ALS Clinical Trials With Generative Artificial Intelligence Technologies - PR Newswire
googlenews
Jun 27, 2023
Science/business updates
external-link
QurAlis Grants Lilly Exclusive Global License for QRL-204, a Potentially First-in-Class Precision Therapy That Restores ...
crunchbase
Jun 4, 2024
Funding-related
external-link
From Safenowitz Fellow to Biotech CEO: Kasper Roet, Ph.D. - ALS Association
googlenews
Jun 28, 2024
New hires
external-link
QurAlis to Present Data That Show TDP-43 Pathology Drives Loss of Synaptic UNC13A Function in Neurodegenerative Diseases Including ALS and Frontotemporal Dementia - PR Newswire
googlenews
Nov 29, 2023
Science/business updates
external-link
QurAlis to Present at H.C. Wainwright BioConnect 2022 Virtual Conference
crunchbase
Jan 3, 2022
Science/business updates
external-link
QurAlis Presents at ALS Drug Development Summit 2022
crunchbase
May 25, 2022
Science/business updates
external-link
QurAlis Doses First Patient With ALS in Phase 1 Clinical Trial Evaluating QRL-101, a First-in-Class Kv7 Precision Therapy for ALS
crunchbase
Dec 4, 2024
Science/business updates
external-link
QurAlis raises $42M in Series A round to develop therapies for ALS
crunchbase
Jun 18, 2020
Funding-related
external-link
QurAlis Presents Data About STATHMIN-2 Role in Neuronal Disease Biology and TDP-43 Biomarker Identification at AD/PD™ 2022 - PR Newswire
googlenews
Mar 15, 2022
Science/business updates
external-link
Eli Lilly adds ALS drug prospect with QurAlis deal - BioPharma Dive
googlenews
Jun 3, 2024
Funding-related
external-link
ALS biotech QurAlis gets $88M boost from four pharmas for pair of PhI studies
crunchbase
Mar 9, 2023
Funding-related
external-link
QurAlis Expands its Industry-Leading Precision Medicine Approach in Splicing Targets Beyond Neurodegeneration Into Fragile X Syndrome (FXS) - PR Newswire
googlenews
Jun 25, 2024
Science/business updates
external-link
QurAlis to Participate at the Piper Sandler 36th Annual Healthcare Conference
web
Dec 23, 2024
Science/business updates
external-link
QurAlis Expands its Industry-Leading Precision Medicine Approach in Splicing Targets Beyond Neurodegeneration ...
crunchbase
Jun 25, 2024
Science/business updates
external-link
First ALS patient dosed in Phase 1 trial testing Quralis’ QRL-101 - ALS News Today
googlenews
Dec 9, 2024
Science/business updates
external-link
QurAlis to Present at H.C. Wainwright Private Company Showcase
crunchbase
Jul 27, 2022
Science/business updates
external-link
Quralis licenses QRL-204 to Lilly for up to $622M - BioWorld Online
googlenews
Jun 3, 2024
Funding-related
external-link
QurAlis Doses First Patient With ALS in Phase 1 Clinical Trial Evaluating QRL-101, a First-in-Class Kv7 Precision Therapy for ALS
web
Dec 23, 2024
Science/business updates
external-link
QurAlis Doses First Participant Cohort in Phase 1 Multiple-Ascending Dose (MAD) Clinical Trial Evaluating QRL-101, a First-in-Class Kv7 Precision Therapy for ALS - The Eastern Progress Online
googlenews
Dec 10, 2024
Science/business updates
external-link
QurAlis to Participate at the Piper Sandler 36th Annual Healthcare Conference
crunchbase
Nov 25, 2024
Science/business updates
external-link
QurAlis to Participate at the Stifel 2024 Healthcare Conference - BioSpace
googlenews
Nov 13, 2024
Science/business updates
external-link
QurAlis to Participate at the Stifel 2024 Healthcare Conference
web
Dec 23, 2024
Science/business updates
external-link
QurAlis to Participate in Upcoming Investor Conferences in February
crunchbase
Feb 5, 2024
Funding-related
external-link
QurAlis' ANQUR Clinical Trial of QRL-201 in ALS Advances to Dose Range-Finding (DRF) Phase With First Participant Dosed - PR Newswire
googlenews
Nov 19, 2024
Science/business updates
external-link
QurAlis to Present Data That Show its Splice-Switching ASOs Restore UNC13A Function in ALS and Frontotemporal ...
crunchbase
Mar 4, 2024
Science/business updates
external-link
Doug Williamson among three senior appointments at QurAlis - The Pharma Letter
googlenews
Jun 11, 2024
New hires
external-link
QurAlis to Present Data Showing Link Between TDP-43 Pathology and Role of UNC13A in Neuronal Biology Related ...
crunchbase
Sep 6, 2023
Science/business updates
external-link
Eli Lilly gains rights to QurAlis' neurodegenerative disease therapy in deal worth over $620m - PMLiVE
googlenews
Jun 5, 2024
Funding-related
external-link
Lilly gilds neuro pipeline, paying QurAlis $45M for preclinical ALS, dementia prospect
crunchbase
Jun 4, 2024
Funding-related
external-link
QurAlis Receives Clinical Trial Authorisation (CTA) in the U.K. for QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS - PR Newswire
googlenews
Jul 11, 2023
Science/business updates
external-link
QurAlis' FlexASOs Show High Potency and Improved Safety Over Standard ASOs - PR Newswire
googlenews
Jun 8, 2023
Science/business updates
external-link
QurAlis Expands Leadership Team With Doug Williamson, M.D., as Chief Medical Officer and Jason Brown, MBA, as Chief Financial Officer and Appoints Shafique Virani, M.D., to Board of Directors - PR New
googlenews
Jun 11, 2024
New hires
external-link
QurAlis to Participate in Upcoming Investor Conferences in June
crunchbase
Jun 1, 2023
Funding-related
external-link
New developments and opportunities in drugs being trialed for amyotrophic lateral sclerosis from 2020 to 2022 - Frontiers
googlenews
Feb 7, 2024
Science/business updates
external-link
QurAlis to Participate at the Piper Sandler 36th Annual Healthcare Conference - PR Newswire
googlenews
Nov 25, 2024
Science/business updates
external-link
QurAlis Reveals Newest Program Targeting UNC13A RNA Mis-splicing Incorporating its FlexASO™ Platform
crunchbase
Mar 20, 2023
Science/business updates
external-link
Treatment of neurological diseases using modulators of kcnq2 gene transcripts
crunchbase
Dec 2, 2022
Science/business updates
external-link
May this holiday season bring peace, joy, love, and light to you and yours. Happy Holidays and Happy New Year from QurAlis!
linkedin
Dec 23, 2024
None of the above
external-link
QurAlis Announces Development Candidate for ALS Targeting STATHMIN-2
crunchbase
Sep 14, 2021
Science/business updates
external-link
QurAlis Announces Agreement to Strengthen ALS Pipeline - Business Wire
googlenews
Jul 1, 2020
Science/business updates
external-link
Surprise medical breakthrough in MND fight
crunchbase
Sep 1, 2023
Science/business updates
external-link
Abstracts Online - International Symposium on ALS/MND
linkedin
Dec 9, 2024
Science/business updates
external-link
ALS QRL-201 therapy: QurAlis begins phase 1 clinical study - Drug Discovery & Development
googlenews
Apr 7, 2023
Science/business updates
external-link
QurAlis opens European HQ to drive commercialization
crunchbase
Jan 4, 2024
Science/business updates
external-link
QurAlis and Unlearn.AI collaborate to optimise generative AI-powered ALS clinical trials - Clinical Trials Arena
googlenews
Jun 30, 2023
Science/business updates
external-link
QurAlis links with Unlearn to leverage machine learning in ...
crunchbase
Jun 28, 2023
Science/business updates
external-link
A recent study published in Cell leveraging single-nuclear RNA-seq and ATAC-seq has shed new light on the molecular landscape and complexity of #Alzheimersdisease, #FTD, and #PSP. The research reveale
linkedin
Dec 23, 2024
Science/business updates
external-link
QurAlis' FlexASOs Show High Potency and Improved Safety Over Standard ASOs
crunchbase
Jun 8, 2023
Science/business updates
external-link
QurAlis’ Biomarker-Driven Approach Attracts $88M in Series B
crunchbase
Mar 9, 2023
Funding-related
external-link
QurAlis’ ANQUR Clinical Trial of QRL-201 in ALS Advances to Dose Range-Finding (DRF) Phase With First Participant Dosed
web
Dec 23, 2024
Science/business updates
external-link
QurAlis Opens European Headquarters in The Netherlands
crunchbase
Jan 16, 2024
Science/business updates
external-link
QurAlis Announces Publication in Molecular Biology of the Cell of Next Generation Drug Screening Platform for ALS Developed by Company Founders - PR Newswire
googlenews
Dec 23, 2021
Science/business updates
external-link
QurAlis’ Biomarker-Driven Approach Attracts $88M in Series B - BioSpace
googlenews
Mar 9, 2023
Funding-related
external-link
Eli Lilly to develop, market ALS therapy for UNC13A function - ALS News Today
googlenews
Jun 11, 2024
Science/business updates
external-link
QurAlis Completes $88 Million Series B Financing Round
crunchbase
Mar 9, 2023
Funding-related
external-link
QurAlis Announces the Appointment of Anne C. Whitaker as Chair of the Board - PR Newswire
googlenews
Jun 21, 2022
New hires
external-link
QurAlis Expands Leadership Team With Doug Williamson, M.D., as Chief Medical Officer and Jason Brown, MBA, as Chief Financial Officer and Appoints Shafique Virani, M.D., to Board of Directors
crunchbase
Jul 1, 2024
New hires
external-link
QurAlis Presents! QurAlis' CEO and co-founder Kasper Roet presented a corporate overview at the Piper Sandler 36th Annual Healthcare Conference held last week in New York, NY. #precisionmedicine #neur
linkedin
Dec 16, 2024
Science/business updates
external-link
© 2024 Work In Biotech LLC
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com